Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy

Abstract The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received either subcutaneous Ig (IgPro20; Hizentra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/864b1de80a0d49abab9c2cf35b4c5ae2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares